What is at-home healthcare and why is it growing?

At-home healthcare refers to medical treatments and services delivered in patients' homes rather than in hospitals or clinics. It's growing because it offers greater convenience, reduces healthcare costs, improves patient comfort, and often leads to better treatment adherence. Recent FDA approvals, like the at-home Alzheimer's treatment, are accelerating this trend.

How does the FDA approval of at-home Alzheimer's treatment impact investments?

The FDA's approval of an injectable, at-home version of Leqembi represents a significant shift in how complex treatments are delivered. This creates investment opportunities in companies that provide the infrastructure for home care, including medical devices, patient monitoring systems, telehealth services, and home infusion companies.

What types of companies benefit from the at-home healthcare trend?

Companies across the entire at-home care ecosystem can benefit, including medical device manufacturers that create home-use equipment, telehealth platforms that enable remote consultations, patient monitoring technology providers, home infusion services, and healthcare companies that facilitate the transition from clinic to home care.

What does 'Market Cap' mean when evaluating these healthcare stocks?

Market Cap (market capitalisation) is the total value of a company's shares in the stock market. It's calculated by multiplying the current share price by the number of outstanding shares. A larger market cap often indicates a more established company, while smaller market caps might suggest higher growth potential but also higher risk.

What is 'Potential Profit %' and how should I interpret it?

Potential Profit % represents analysts' projections of how much a stock's price might increase over a specific period, typically 12 months. It's based on professional analysis of the company's prospects, but remember that all investments carry risk and actual returns may differ significantly from projections.

17 handpicked stocks

At-Home Healthcare Stocks Explained | FDA Approval

The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.

Han Tan | Market Analyst

Updated 2 days ago | Published at August 30